Active ingredient: Olmesartan Medoxomil

How often in a day do you take medicine? How many times?
advertisement

Olmesartan Medoxomil uses


Pharmacological action

Olmesartan Medoxomil is an antihypertensive agent, angiotensin II receptor blocker. This medication has a high selectivity to angiotensin II receptor type 1 which are implemented with the participation of the main effects of angiotensin II. By blocking these receptors Olmesartan Medoxomil prevents and eliminates the vasoconstrictor action of angiotensin II, causes a secondary increase in plasma renin activity due to elimination of negative feedback for renin release and a direct reduction in aldosterone secretion.

When hypertension Olmesartan Medoxomil causes dose-dependent, prolonged reduction of blood pressure.

There are no details about the development of arterial hypotension after the first dose of Olmesartan Medoxomil, tachyphylaxis during prolonged treatment and withdrawal.

When taking first time Olmesartan Medoxomil provides an effective and mild reduction of blood pressure within 24 hours. Maximum antihypertensive effect is achieved after 8 weeks of the therapy, although a significant effect of blood pressure lowering marked only in 2 weeks of the treatment.

Pharmacokinetics

Olmesartan Medoxomil is a pro-drug. It quickly turns into a pharmacologically active metabolite of olmesartan under the influence of esterases in the intestinal mucosa and blood of portal vein during absorption from the gastrointestinal tract. In blood plasma or secretions nondecomposed Olmesartan Medoxomil or unmodified side chain medoxomil group was not been determined. Cmax of olmesartan in plasma levels reached an average of approximately 2 hours after ingestion and increases almost linearly with increasing dose to 80 mg. Simultaneous ingestion does not affect the bioavailability of olmesartan. Olmesartan binding to plasma proteins is 99.7% but the potential for clinically significant shift values of binding to proteins in the interaction of olmesartan with other drugs that have a high degree of protein binding is low (this is confirmed by the fact that there is no clinically significant interaction between warfarin and olmesartan). Olmesartan is excreted in the urine (approximately 40%) and bile (approximately 60%), T1/2 is 10-15 hours. Cumulation of olmesartan is not marked.

advertisement

Why is Olmesartan Medoxomil prescribed?

Essential arterial hypertension.

Dosage and administration

Olmesartan Medoxomil is administered orally on a daily basis. The initial dose is 10 mg / day. When inefficiency the dose increases up to the optimum 20 mg / day. If necessary the dose may be increased to the maximum 40 mg / day.

For elderly patients dosage adjustment is not required. If necessary increasing the daily dose to a maximum of 40 mg / day improvement should be under careful control of blood pressure. For patients with impaired mild or moderate renal function the maximum daily dose is 20 mg.

Olmesartan Medoxomil side effects, adverse reactions

Cardio-vascular system: hypotension, angina pectoris.

Hemopoietic system: thrombocytopenia.

CNS: vertigo, dizziness, headache, asthenia syndrome (fatigue, lethargy, malaise).

Respiratory system: bronchitis, pharyngitis, rhinitis, cough.

Digestive system: diarrhea, dyspepsia, gastroenteritis, abdominal pain, nausea, vomiting, increased liver enzymes.

Dermatological reactions: itching, rash, angioedema, atopic dermatitis, facial edema, urticaria.

Musculoskeletal system: arthritis, back pain, bone pain, muscle cramps, myalgia, increased activity of CK.Urinary system: hematuria, urinary tract infection.

Metabolism: hypertriglyceridemia, hyperuricemia, hyperkalemia, increased serum creatinine and urea in serum, peripheral edema.

Other: chest pain, flu-like symptoms.

Olmesartan Medoxomil contraindications

Obstruction of the biliary tract, pregnancy, lactation, childhood and adolescence under the age of 18 years.

Using during pregnancy and breastfeeding

Olmesartan Medoxomil is contraindicated for use during pregnancy and lactation.

Special instructions

Due to the lack of sufficient clinical experience does not recommended the use of Olmesartan Medoxomil in patients with severe renal insufficiency (creatinine clearance < 20 mL / min), patients with impaired liver function.

Olmesartan Medoxomil used with caution in patients with stenosis of the aortic or mitral valves or obstructive hypertrophic cardiomyopathy.

In the case of previous intensive therapy with diuretics, human salt-free diet, diarrhea and / or vomiting after the first dose may been developed hypotension as a result of reducing the BCC. Thats why it is necessary to eliminate the possibility of hypovolemia before starting treatment with Olmesartan Medoxomil.

Olmesartan Medoxomil should be used with caution for patients with heart failure, kidney disease, renal artery stenosis in both or only one kidney because of the risk of acute hypotension, azotemia, oliguria, acute renal failure.

When treating patients with impaired renal function it is recommended periodic monitoring of potassium and creatinine in serum.

It is not recommended of Olmesartan Medoxomil using in patients with primary hyperaldosteronism.

It should be borne in mind that excessive lowering of blood pressure in patients with coronary artery disease or atherosclerosis of cerebral vessels may lead to the development of myocardial infarction or ischemic stroke.

While taking of Olmesartan Medoxomil occasionally there may be dizziness or fatigue which should be considered in the application of patients, control of vehicles and / or engaged in other potentially hazardous activities.

Olmesartan Medoxomil drug interactions

Simultaneous administration of Olmesartan Medoxomil with:

  • other antihypertensive drugs may increase the hypotensive effect;
  • NSAIDs may reduce hypotensive effects and increased risk of acute renal failure;
  • after therapy with antacids there was detected of decreasing bioavailability of Olmesartan Medoxomil;
  • lithium medications increases the toxicity of the latter (the combination is not recommended).The risk of developing hyperkalemia is increased while the taking of Olmesartan Medoxomil with potassium-sparing diuretics, medications containing potassium or with other drugs that can cause increased potassium levels in blood serum, for example, with heparin (a combination not recommended).

    Olmesartan Medoxomil in case of emergency / overdose

    Symptoms: pronounced reduction in blood pressure, tachycardia.

    Treatment: when pronounced reduction of blood pressure is recommended to lay the patient on his back and lifted his legs. There is recommended a gastric lavage and / or reception of activated charcoal therapy aimed at correcting dehydration and violations of water-salt metabolism, supplementation of BCC.

    Olmesartan Medoxomil available forms, composition, doses:


    Indications and Usages:

    ATC codes:


    ICD-10 codes:


    Olmesartan Medoxomil destination | category:


    advertisement

    Drugs with same active ingredients (Pharmaceutical companies):


    References

    1. Dailymed."BENICAR (OLMESARTAN MEDOXOMIL) TABLET, FILM COATED [DAIICHI SANKYO, INC.]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).

    Frequently asked Questions

    Can i drive or operate heavy machine after consuming Olmesartan Medoxomil?

    Depending on the reaction of the Olmesartan Medoxomil after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Olmesartan Medoxomil not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

    Is Olmesartan Medoxomil addictive or habit forming?

    Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

    Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

    advertisement

    Review

    sdrugs.com conducted a study on Olmesartan Medoxomil, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Olmesartan Medoxomil consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

    Visitor reports

    Visitor reported useful

    No survey data has been collected yet

    Visitor reported side effects

    No survey data has been collected yet

    Visitor reported price estimates

    No survey data has been collected yet

    One visitor reported frequency of use

    How often in a day do you take the medicine?
    Are you taking the Olmesartan Medoxomil drug as prescribed by the doctor?

    Few medications can be taken Once in a day more than prescribed when the doctor's advice mentions the medicine can be taken according to frequency or severity of symptoms. Most times, be very careful and clear about the number of times you are taking the medication. The report of sdrugs.com website users about the frequency of taking the drug Olmesartan Medoxomil is mentioned below.
    Visitors%
    Once in a day1
    100.0%

    Visitor reported doses

    No survey data has been collected yet

    Visitor reported time for results

    No survey data has been collected yet

    Visitor reported administration

    No survey data has been collected yet

    One visitor reported age

    Visitors%
    > 601
    100.0%

    Visitor reviews


    There are no reviews yet. Be the first to write one!


    Your name: 
    Email: 
    Spam protection:  < Type 29 here

    The information was verified by Dr. Rachana Salvi, MD Pharmacology

    © 2002 - 2024 "sdrugs.com". All Rights Reserved